CY1119220T1 - Μονοκυκλικο παραγωγο πυριδινης - Google Patents

Μονοκυκλικο παραγωγο πυριδινης

Info

Publication number
CY1119220T1
CY1119220T1 CY20171100631T CY171100631T CY1119220T1 CY 1119220 T1 CY1119220 T1 CY 1119220T1 CY 20171100631 T CY20171100631 T CY 20171100631T CY 171100631 T CY171100631 T CY 171100631T CY 1119220 T1 CY1119220 T1 CY 1119220T1
Authority
CY
Cyprus
Prior art keywords
group
atom
hydrogen atom
alkoxy
alkyl
Prior art date
Application number
CY20171100631T
Other languages
English (en)
Inventor
Setsuo Funasaka
Toshimi Okada
Keigo Tanaka
Satoshi Nagao
Isao Ohashi
Yoshinobu Yamane
Yusuke Nakatani
Yuki KAROJI
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of CY1119220T1 publication Critical patent/CY1119220T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Η παρούσα εφεύρεση αποκαλύπτει μια ένωση που αντιπροσωπεύεται από τον ακόλουθο τύπο (ΙΑ) ή ένα φαρμακευτικώς αποδεκτό άλας αυτής: όπου το n αντιπροσωπεύει 0 έως 2· το Α αντιπροσωπεύει μια ομάδα αρυλενίου ή μία ομάδα ετεροαρυλενίου· το G αντιπροσωπεύει έναν απλό δεσμό, ένα άτομο οξυγόνου ή -CΗ2-· το Ε αντιπροσωπεύει ένα μη-αρωματικό ετεροκυκλικό δακτύλιο που περιέχει άζωτο· το R1 αντιπροσωπεύει ομάδα αλκοξυ, μια ομάδα αλκοξυ αλκοξυ ή τα παρόμοια· το R2 αντιπροσωπεύει ένα άτομο υδρογόνου, ένα άτομο αλογόνου, μια ομάδα υδροξυλίου, μια ομάδα αλκυλίου, μια ομάδα υδροξυ αλκυλίου, μια μη-αρωματική ετεροκυκλική ομάδα που περιέχει άζωτο ή τα παρόμοια· το R3 αντιπροσωπεύει ένα άτομο υδρογόνου, μια ομάδα αλκυλίου, μια ομάδα αλκόξυ ή τα παρόμοια· και το R4 αντιπροσωπεύει μια ομάδα C1-6 αλκυλίου, υπό την προϋπόθεση ότι όταν το Ε αντιπροσωπεύει έναν δακτύλιο αζετιδίνης και το R2 ή το R3 είναι παρόν σε ένα άτομο αζώτου στον δακτύλιο αζετιδίνης, το R2 ή το R3 δεν αντιπροσωπεύει ένα άτομο υδρογόνου.
CY20171100631T 2013-02-20 2017-06-15 Μονοκυκλικο παραγωγο πυριδινης CY1119220T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361766922P 2013-02-20 2013-02-20
PCT/JP2014/053819 WO2014129477A1 (ja) 2013-02-20 2014-02-18 単環ピリジン誘導体

Publications (1)

Publication Number Publication Date
CY1119220T1 true CY1119220T1 (el) 2018-02-14

Family

ID=51351646

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100631T CY1119220T1 (el) 2013-02-20 2017-06-15 Μονοκυκλικο παραγωγο πυριδινης

Country Status (35)

Country Link
US (1) US8933099B2 (el)
EP (1) EP2960238B1 (el)
JP (2) JP5600229B1 (el)
KR (1) KR102050128B1 (el)
CN (1) CN105073730B (el)
AR (1) AR094812A1 (el)
AU (1) AU2014219811B2 (el)
BR (1) BR112015019790B1 (el)
CA (1) CA2901585C (el)
CL (1) CL2015002311A1 (el)
CY (1) CY1119220T1 (el)
DK (1) DK2960238T3 (el)
ES (1) ES2628495T3 (el)
HK (1) HK1215949A1 (el)
HR (1) HRP20170873T1 (el)
HU (1) HUE032931T2 (el)
IL (1) IL240623B (el)
JO (1) JO3261B1 (el)
LT (1) LT2960238T (el)
ME (1) ME02755B (el)
MX (1) MX361870B (el)
MY (1) MY178760A (el)
NZ (1) NZ711101A (el)
PE (1) PE20151509A1 (el)
PH (1) PH12015501813A1 (el)
PL (1) PL2960238T3 (el)
PT (1) PT2960238T (el)
RS (1) RS56064B1 (el)
RU (1) RU2645352C2 (el)
SG (1) SG11201506488WA (el)
SI (1) SI2960238T1 (el)
TW (4) TWI641602B (el)
UA (1) UA116794C2 (el)
WO (1) WO2014129477A1 (el)
ZA (1) ZA201505941B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951047B2 (en) * 2014-08-18 2018-04-24 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
RU2712222C2 (ru) * 2015-03-25 2020-01-27 Нэшнл Кэнсер Сентер Терапевтическое средство против рака желчных протоков
CN115177619A (zh) * 2015-12-17 2022-10-14 卫材R&D管理有限公司 用于乳腺癌的治疗剂
CN107098884A (zh) * 2016-02-19 2017-08-29 中国科学院上海药物研究所 一类取代的氨基吡啶类化合物及其制备和用途
BR112020003849A2 (pt) * 2017-10-12 2020-09-08 Eisai R&D Management Co., Ltd. composição farmacêutica compreendendo inibidor seletivo de tirosina quinase fgfr
BR112020017922A2 (pt) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. Agente terapêutico para carcinoma hepatocelular
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230149381A1 (en) 2020-04-17 2023-05-18 Eisai R&D Management Co., Ltd. Breast cancer therapeutic agent
MX2023000060A (es) 2020-07-31 2023-02-01 Eisai R&D Man Co Ltd Agente terapeutico para cancer de mama.
WO2022092085A1 (ja) 2020-10-28 2022-05-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
TW202328098A (zh) 2021-08-31 2023-07-16 日商衛材R&D企管股份有限公司 單環吡啶衍生物的合成中間體之製造方法
TW202328099A (zh) 2021-08-31 2023-07-16 日商衛材R&D企管股份有限公司 單環吡啶衍生物之製造方法
WO2023174400A1 (zh) * 2022-03-18 2023-09-21 上海润石医药科技有限公司 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
DE60126997T2 (de) 2000-10-20 2007-10-25 Eisai R&D Management Co., Ltd. Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
JP4071636B2 (ja) 2001-04-03 2008-04-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 シクロオクタノン誘導体およびシクロデカノン誘導体、およびその用途
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
MXPA05001536A (es) * 2002-08-30 2005-04-19 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
MXPA05010765A (es) 2003-04-10 2005-12-12 Hoffmann La Roche Compuestos pirimido.
US20050256154A1 (en) 2004-05-04 2005-11-17 Kin-Chun Luk 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
MX2007014782A (es) * 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
JP5153645B2 (ja) 2005-12-21 2013-02-27 ノバルティス アーゲー Ｆｇｆ阻害剤であるピリミジニルアリールウレア誘導体
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1891955A1 (en) 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
CA2672213C (en) 2006-12-22 2016-02-16 Astex Therapeutics Limited Bicyclic amine derivatives as protein tyrosine kinase inhibitors
JP5442448B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド Ｆｇｆｒインヒビターとしての二環式ヘテロ環式化合物
EP2158470A1 (en) 2007-06-25 2010-03-03 Qinetiq Limited Preconcentrator device incorporating a polymer of intrinsic microporosity
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
WO2009076660A2 (en) * 2007-12-13 2009-06-18 Tyratech, Inc. Organic absorbent material and uses thereof
CL2008003675A1 (es) * 2007-12-13 2009-03-20 Wyeth Corp Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparacion, composicion farmaceutica, util para reducir la actividad incrementada de una enzima en un mamifero, en donde dicha enzima es una proteina quinasa, destinado al tratamiento de la inflamacion, asma, colitis, esclerosis multiple, soriasis, artritis reumatoide.
CN102036963B (zh) 2008-05-23 2013-08-21 诺瓦提斯公司 作为蛋白酪氨酸激酶抑制剂的喹啉类和喹喔啉类衍生物
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
EP2328872A1 (en) 2008-06-19 2011-06-08 AstraZeneca AB Pyrazole compounds 436
CA2748174A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
EP2379551A1 (en) 2008-12-30 2011-10-26 ArQule, Inc. Substituted pyrazolo [3, 4-b]pyridine compounds
JP5739820B2 (ja) 2008-12-30 2015-06-24 アークル インコーポレイテッド 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミン化合物
US9002427B2 (en) 2009-03-30 2015-04-07 Lifewave Biomedical, Inc. Apparatus and method for continuous noninvasive measurement of respiratory function and events
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
EP2270043A1 (en) 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
FR2947546B1 (fr) 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
CN102574836B (zh) 2009-08-07 2014-04-16 中外制药株式会社 氨基吡唑衍生物
WO2011051425A1 (en) 2009-10-30 2011-05-05 Novartis Ag N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
PT2657233E (pt) 2012-01-19 2014-10-24 Taiho Pharmaceutical Co Ltd Composto de alcinil-benzeno substituído nas posições 3 e 5 e um seu sal
JP5343177B1 (ja) 2012-02-28 2013-11-13 アステラス製薬株式会社 含窒素芳香族へテロ環化合物
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
BR112014030812B1 (pt) 2012-06-13 2022-11-08 Incyte Holdings Corporation Compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr
RU2019102203A (ru) 2012-07-11 2019-03-05 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
EA031631B1 (ru) 2012-09-27 2019-01-31 Чугаи Сеияку Кабушики Каиша Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑

Also Published As

Publication number Publication date
JO3261B1 (ar) 2018-09-16
UA116794C2 (uk) 2018-05-10
RS56064B1 (sr) 2017-10-31
TWI672139B (zh) 2019-09-21
PH12015501813A1 (en) 2015-12-07
MX2015010698A (es) 2016-04-11
BR112015019790A2 (pt) 2017-07-18
JPWO2014129477A1 (ja) 2017-02-02
US8933099B2 (en) 2015-01-13
BR112015019790B1 (pt) 2020-12-01
EP2960238B1 (en) 2017-04-05
RU2645352C2 (ru) 2018-02-21
TWI672296B (zh) 2019-09-21
RU2015134558A (ru) 2017-03-24
TW201902889A (zh) 2019-01-16
LT2960238T (lt) 2017-07-10
ME02755B (me) 2018-01-20
AR094812A1 (es) 2015-08-26
ES2628495T3 (es) 2017-08-03
TW201900169A (zh) 2019-01-01
KR102050128B1 (ko) 2019-11-28
WO2014129477A1 (ja) 2014-08-28
AU2014219811A1 (en) 2015-09-03
EP2960238A4 (en) 2016-08-17
JP5600229B1 (ja) 2014-10-01
HK1215949A1 (zh) 2016-09-30
MX361870B (es) 2018-12-18
TW201900168A (zh) 2019-01-01
EP2960238A1 (en) 2015-12-30
TWI672140B (zh) 2019-09-21
US20140235614A1 (en) 2014-08-21
DK2960238T3 (en) 2017-06-26
PL2960238T3 (pl) 2017-09-29
TWI641602B (zh) 2018-11-21
CL2015002311A1 (es) 2016-02-05
CA2901585C (en) 2019-09-24
HRP20170873T1 (hr) 2017-09-08
AU2014219811B2 (en) 2017-09-28
CN105073730B (zh) 2017-10-13
MY178760A (en) 2020-10-20
PE20151509A1 (es) 2015-10-18
KR20150118151A (ko) 2015-10-21
PT2960238T (pt) 2017-06-05
SG11201506488WA (en) 2015-09-29
SI2960238T1 (sl) 2017-07-31
IL240623B (en) 2019-03-31
IL240623A0 (en) 2015-10-29
NZ711101A (en) 2018-08-31
CA2901585A1 (en) 2014-08-28
TW201439085A (zh) 2014-10-16
CN105073730A (zh) 2015-11-18
HUE032931T2 (en) 2017-11-28
ZA201505941B (en) 2016-07-27
JP2014237707A (ja) 2014-12-18

Similar Documents

Publication Publication Date Title
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
CY1122614T1 (el) 11-υδροξυλ-6-υποκατεστημενα-παραγωγα χολικων οξεων και συζευγματα αμινοξεων αυτων ως ρυθμιστες υποδοχεων χ φαρνεσοειδων
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CY1124620T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
CY1119422T1 (el) Παραγωγα μπετουλινης
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
CY1120173T1 (el) Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης
AR099400A1 (es) Compuesto heterocíclico fusionado
CR20150509A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
CY1123670T1 (el) Κρυσταλλικο παραγωγο 6,7-ακορεστης-7-καρβαμοϋλ μορφινανης, και μεθοδος για την παραγωγη αυτου
CY1124537T1 (el) Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα
CY1123154T1 (el) Παραγοντας ενισχυσης της επιδρασης αποκαταστασης μετα απο νευρικη βλαβη που περιλαμβανει ενα παραγωγο αλκυλαιθερα ή ενα αλας αυτου
UA113643C2 (xx) N-цикліламіди як нематоциди
CY1121626T1 (el) Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου
CY1114452T1 (el) Ενωσεις πυρρολιου
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
CY1119583T1 (el) Φαινοξυαιθυλο παραγωγα κυκλικης αμινης και η δραστικοτητα τους ως τροποποιητες του ερ4 υποδοχεα
BR112016001979A2 (pt) composto de tetrazolinona e uso do mesmo
PE20160523A1 (es) Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis
CY1119425T1 (el) Ενωσεις φαινοξυαιθυλο πιπεριδινης
CY1124643T1 (el) Νεα ενωση και φαρμακευτικα αποδεκτο αλας αυτης
AR095523A1 (es) Derivados piridin-4-ilo
CY1119296T1 (el) Ενωση δικαρβοξυλικου οξεος